SLNO
NASDAQ · Biotechnology
Soleno Therapeutics Inc
$31.04
-0.68 (-2.14%)
Financial Highlights (FY 2026)
Revenue
186.85M
Net Income
20.50M
Gross Margin
98.6%
Profit Margin
11.0%
Rev Growth
+298.9%
D/E Ratio
0.11
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 98.6% | 66.0% | 66.0% | 66.0% |
| Operating Margin | 4.9% | 11.9% | 11.9% | 10.3% |
| Profit Margin | 11.0% | 9.4% | 9.8% | 8.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 186.85M | 785.64M | 787.82M | 714.81M |
| Gross Profit | 184.20M | 518.23M | 519.67M | 471.51M |
| Operating Income | 9.23M | 93.63M | 93.92M | 73.52M |
| Net Income | 20.50M | 73.80M | 76.85M | 57.56M |
| Gross Margin | 98.6% | 66.0% | 66.0% | 66.0% |
| Operating Margin | 4.9% | 11.9% | 11.9% | 10.3% |
| Profit Margin | 11.0% | 9.4% | 9.8% | 8.1% |
| Rev Growth | +298.9% | +24.2% | +9.0% | +11.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 85.53M | 238.43M | 275.87M | 215.89M |
| Total Equity | 771.95M | 1.13B | 1.17B | 1.24B |
| D/E Ratio | 0.11 | 0.21 | 0.24 | 0.17 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 11.22M | 123.66M | 121.59M | 105.95M |
| Free Cash Flow | — | 65.88M | 73.67M | 75.75M |